Cytochrome P450-oxidoreductase (POR) deficiency (ORD): Difference between revisions
Jump to navigation
Jump to search
| Line 31: | Line 31: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased | ||
|- | |- | ||
![[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]] | |||
| | | | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
| Line 47: | Line 47: | ||
* [[Hypotension]] and [[hyperkalemia]] | * [[Hypotension]] and [[hyperkalemia]] | ||
|- | |- | ||
![[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |||
| | | | ||
* [[Deoxycorticosterone]] | * [[Deoxycorticosterone]] | ||
| Line 61: | Line 61: | ||
* [[Virilization]] | * [[Virilization]] | ||
|- | |- | ||
![[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]] | |||
| | | | ||
* [[Deoxycorticosterone]] | * [[Deoxycorticosterone]] | ||
| Line 79: | Line 79: | ||
* Minimal [[body hair]] | * Minimal [[body hair]] | ||
|- | |- | ||
![[3 beta-hydroxysteroid dehydrogenase deficiency]] | |||
| | | | ||
* [[Dehydroepiandrosterone]] | * [[Dehydroepiandrosterone]] | ||
| Line 91: | Line 91: | ||
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis | * 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis | ||
|- | |- | ||
! Gestational [[hyperandrogenism]] | |||
| colspan="2" | | | colspan="2" | | ||
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | * Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | ||
| Line 103: | Line 103: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Cytochrome P450-oxidoreductase (POR) deficiency is a | Cytochrome P450-oxidoreductase (POR) deficiency is a rere disease with unknown [[prevalence]].<ref name="pmid14758361">{{cite journal |vauthors=Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K, Miller WL |title=Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome |journal=Nat. Genet. |volume=36 |issue=3 |pages=228–30 |year=2004 |pmid=14758361 |doi=10.1038/ng1300 |url=}}</ref><ref name="pmid18559916">{{cite journal |vauthors=Hershkovitz E, Parvari R, Wudy SA, Hartmann MF, Gomes LG, Loewental N, Miller WL |title=Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=93 |issue=9 |pages=3584–8 |year=2008 |pmid=18559916 |pmc=2567854 |doi=10.1210/jc.2008-0051 |url=}}</ref> | ||
== Diagnosis == | == Diagnosis == | ||
=== Symptoms and physical Examination === | === Symptoms and physical Examination === | ||
| Line 113: | Line 113: | ||
=== Medical Therapy === | === Medical Therapy === | ||
The mainstay of therapy for cytochrome P450-oxidoreductase deficiency is [[hydrocortisone]] to replace [[glucocorticoid]] deficiency. Gender-appropriate replacement of [[androgens]] or [[estrogens]] with [[progestins]] is necessary at the [[puberty]] time. | The mainstay of therapy for cytochrome P450-oxidoreductase deficiency is [[hydrocortisone]] to replace [[glucocorticoid]] deficiency. Gender-appropriate replacement of [[androgens]] or [[estrogens]] with [[progestins]] is necessary at the [[puberty]] time. | ||
* Preferred regiemen: [[hydrocortisone]] oral, 15 to 25 mg/day in 2 to 3 divided doses | |||
=== Surgery === | === Surgery === | ||
The reconstruction surgery for [[ambiguous genitalia]] in [[genetically]] male patients may be applied.<ref name="pmid11344932">{{cite journal |vauthors=Schnitzer JJ, Donahoe PK |title=Surgical treatment of congenital adrenal hyperplasia |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=1 |pages=137–54 |year=2001 |pmid=11344932 |doi= |url=}}</ref> | The reconstruction surgery for [[ambiguous genitalia]] in [[genetically]] male patients may be applied.<ref name="pmid11344932">{{cite journal |vauthors=Schnitzer JJ, Donahoe PK |title=Surgical treatment of congenital adrenal hyperplasia |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=1 |pages=137–54 |year=2001 |pmid=11344932 |doi= |url=}}</ref> | ||
Revision as of 18:11, 20 September 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Synonyms and keywords: ORD, POR deficiency, P450-oxidoreductase cytochrome deficiency
Overview
Cytochrome P450-oxidoreductase (POR) deficiency is a type of congenital adrenal hyperplasia that caused by mutations in the flavoprotein co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase). Severe Undervirilization in boys and severe virilization in girls and Antley-Bixler syndrome of craniofacial malformations are clinical finding of this disease. The mainstay of therapy for cytochrome P450-oxidoreductase deficiency is hydrocortisone to replace glucocorticoid deficiency.
Historical Perspective
In 1865, Luigi De Crecchio, an Italian pathologist was the first who discovered Congenital adrenal hyperplasia.[1]
Classification
There is no established classification system for cytochrome P450-oxidoreductase deficiency.
Pathophysiology
The cytochrome P450 oxidoreductase (POR) enzyme serves as an electron donor enzyme for many enzymes such as steroid synthesis enzymes CYP17A1, and CYP21A2. Cytochrome P450-oxidoreductase deficiency is characterized by combined CYP17A1 and CYP21A2 deficiency.
- CYP17A1 encodes17α-hydroxylase/17,20α-hydroxylase, a cytochrome P450 enzyme which acts upon:
- Pregnenolone and progesterone to add a hydroxyl (-OH) group at carbon 17 of the steroid D ring (the hydroxylase activity).
- 17-hydroxyprogesterone and 17-hydroxypregnenolone to split the side chain off the steroid nucleus.
- CYP21A2 encodes steroid 21-hydroxylase, a cytochrome P450 enzyme which is involved with the biosynthesis of the steroid hormones aldosterone and cortisol.
Also, cytochrome P450 oxidoreductase enzyme serves as a co-factor for an enzyme called lanosterol de-methylase (CYP51A1), which is effective in de novo cholesterol synthesis. In this disease cholesterol loss may lead to craniofacial malformations and Antley-Bixler syndrome (ABS).[2][3][4][5][6]
Causes
Cytochrome P450-oxidoreductase (POR) deficiency is caused by mutations in the flavoprotein that is a co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase).
Differentiating [disease name] from other Diseases
Cytochrome P450-oxidoreductase deficiency must be differentiated from other diseases that cause ambiguous genitalia such as: 21-hydroxylase deficiency, 11-β hydroxylase deficiency, 17 alpha-hydroxylase deficiency, gestational hyperandrogenism.
| Disease name | Steroid status | Important clinical findings | |
|---|---|---|---|
| Increased | Decreased | ||
| Classic type of 21-hydroxylase deficiency |
|
| |
| 11-β hydroxylase deficiency |
|
| |
| 17-α hydroxylase deficiency |
| ||
| 3 beta-hydroxysteroid dehydrogenase deficiency |
| ||
| Gestational hyperandrogenism |
|
| |
Epidemiology and Demographics
Cytochrome P450-oxidoreductase (POR) deficiency is a rere disease with unknown prevalence.[7][8]
Diagnosis
Symptoms and physical Examination
- Severe Undervirilization in boys and severe virilization in girls but pubertal development in this disease is not studied enough.
- Antley-Bixler syndrome (ABS): craniofacial malformations (midface hypoplasia with low set ears and pear-shaped nose, arachnodactyly, clinodactyly, and radio-humeral synostosis.[3][4][5][6]
Laboratory Findings
Genetic testing is the gold standard of diagnosis. Pregnenolone, progesterone and 17-hydroxyprogesterone metabolites are increased and androgen metabolites are decreased.[9]
Treatment
Medical Therapy
The mainstay of therapy for cytochrome P450-oxidoreductase deficiency is hydrocortisone to replace glucocorticoid deficiency. Gender-appropriate replacement of androgens or estrogens with progestins is necessary at the puberty time.
- Preferred regiemen: hydrocortisone oral, 15 to 25 mg/day in 2 to 3 divided doses
Surgery
The reconstruction surgery for ambiguous genitalia in genetically male patients may be applied.[10]
References
- ↑ Delle Piane L, Rinaudo PF, Miller WL (2015). "150 years of congenital adrenal hyperplasia: translation and commentary of De Crecchio's classic paper from 1865". Endocrinology. 156 (4): 1210–7. doi:10.1210/en.2014-1879. PMID 25635623.
- ↑ Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, Ishii T, Numakura C, Sawada H, Nakacho M, Kowase T, Motomura K, Haruna H, Nakamura M, Ohishi A, Adachi M, Tajima T, Hasegawa Y, Hasegawa T, Horikawa R, Fujieda K, Ogata T (2009). "Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients". J. Clin. Endocrinol. Metab. 94 (5): 1723–31. doi:10.1210/jc.2008-2816. PMID 19258400.
- ↑ 3.0 3.1 Peterson RE, Imperato-McGinley J, Gautier T, Shackleton C (1985). "Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia". N. Engl. J. Med. 313 (19): 1182–91. doi:10.1056/NEJM198511073131903. PMID 2932643.
- ↑ 4.0 4.1 Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, Miller WL (2005). "Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis". Am. J. Hum. Genet. 76 (5): 729–49. doi:10.1086/429417. PMC 1199364. PMID 15793702.
- ↑ 5.0 5.1 Kelley RI, Kratz LE, Glaser RL, Netzloff ML, Wolf LM, Jabs EW (2002). "Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia". Am. J. Med. Genet. 110 (2): 95–102. doi:10.1002/ajmg.10510. PMID 12116245.
- ↑ 6.0 6.1 Mann RK, Beachy PA (2004). "Novel lipid modifications of secreted protein signals". Annu. Rev. Biochem. 73: 891–923. doi:10.1146/annurev.biochem.73.011303.073933. PMID 15189162.
- ↑ Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K, Miller WL (2004). "Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome". Nat. Genet. 36 (3): 228–30. doi:10.1038/ng1300. PMID 14758361.
- ↑ Hershkovitz E, Parvari R, Wudy SA, Hartmann MF, Gomes LG, Loewental N, Miller WL (2008). "Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency". J. Clin. Endocrinol. Metab. 93 (9): 3584–8. doi:10.1210/jc.2008-0051. PMC 2567854. PMID 18559916.
- ↑ Shackleton C, Marcos J, Malunowicz EM, Szarras-Czapnik M, Jira P, Taylor NF, Murphy N, Crushell E, Gottschalk M, Hauffa B, Cragun DL, Hopkin RJ, Adachi M, Arlt W (2004). "Biochemical diagnosis of Antley-Bixler syndrome by steroid analysis". Am. J. Med. Genet. A. 128A (3): 223–31. doi:10.1002/ajmg.a.30104. PMID 15216541.
- ↑ Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.